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Abstract
Rationale In a randomised placebo-controlled clinical trial it
is assumed that psychosocial effects of the treatment,
regression to the mean and spontaneous remission are
identical in the drug and placebo group. Consequently, any
difference between the groups can be ascribed to the
pharmacological effects. Previous studies suggest that side
effects of drugs can enhance expectancies of treatment effects
in the drug group compared to the placebo group, and thereby
increase placebo responses in the drug group compared to the
placebo group.
Objectives The hypothesis that side effects of drugs can
enhance expectancies and placebo responses was tested.
Method Painful laser stimuli were delivered to 20 healthy
subjects before and after administration of a drink with 0 or
4 mg/kg caffeine. The drink was administered either with
information that it contained a painkiller or that it was a
placebo. Laser-evoked potentials and reports of pain, expec-
tancy, arousal and stress were measured.
Results Four milligrammes per kilogramme of caffeine
reduced pain. Information that a painkiller was adminis-
tered increased the analgesic effect of caffeine compared to
caffeine administered with no drug information. This effect
was mediated by expectancies. Information and expectan-
cies had no effect on pain intensity when 0 mg/kg was
administered.
Conclusion The analgesic effect of caffeine was increased by
information that a painkiller was administered. This was due
toaninteraction ofthe pharmacological actionofthe drugand
expectancies. Hence, psychosocial effects accompanying a
treatment can differ when an active drug is administered
compared to a placebo.
Keywords Placebo analgesia.Pain.Expectancies
Laser-evoked potentials.Active placebo.Caffeine.
Arousal.Balanced placebo design
Introduction
A placebo is a treatment that mimics active treatment in all
respects except that the placebo is inert. In randomised
double-blind clinical drug trials a placebo group is used as a
control in order toassess the pharmacological effectof a drug.
The logic is that the observed effect in the group receiving the
drug consists of the drug effect and effects due to psycholog-
ical factors, spontaneous remission and regression to the
mean. In the placebo group, the psychological factors,
spontaneous remission and regression to the mean should be
the same as in the drug group. Hence, any difference between
the placebo group and the drug group can be ascribed to the
pharmacological effects of the drug.
Expectations of having received the drug can be
modulated if the subjective effects of a drug inform the
individual that active medication has been administered and
increase expectations of drug effects. Consequently, the
subjectiveeffectsofthedrugintheactivearmofarandomised
double-blind clinical trial may enhance expectations and
placeborespondingcomparedtotheplaceboarm(Dinnerstein
and Halm 1970;F l a t e ne ta l .1999; Lyerly et al. 1964). To
avoid this problem, active placebos may be used instead of,
or in addition to, inert placebos. An active placebo is a drug
that has no effect on the symptom under investigation, but
that mimics the side effects of the active treatment.
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responses, these responses should be larger in the active arm
compared to the placebo arm of a randomised clinical trial,
and the drug response would be overestimated. Reviews of
antidepressant drug trials have found larger effects of the
studydrugwhenithasbeencomparedtoaninertplacebothan
when the study drug has been compared to an active placebo
(Greenberg and Fisher 1994; Kirsch and Sapirstein 1998;
Moncrieff 2003;T h o m s o n1982). This suggests that part of
the difference between the study drug and the inert placebo
are not due to the pharmacological effects of the drug but to
an enhanced placebo effect in the drug group. However, the
hypothesis that side effects can enhance the placebo effect
has not been subjected to an experimental test.
The present experiment tested whether expectations of
pain relief, and the resultant placebo analgesic effect,
were enhanced by the subjective effects of caffeine. It
was hypothesised that the subjective effects of caffeine
would confirm the verbal information that a painkiller
had been administrated, and make subjects more certain
of pain relief.
A within-subjects balanced placebo design (Ross et al.
1962) was used. Information that a painkiller had been or
had not been administered was crossed with administra-
tion of 0 or 4 mg/kg body weight caffeine. Caffeine
increased subjective and physiological arousal at doses
below 100 mg (Silverman and Griffiths 1992), and was
hypothesised to act as an active placebo with little or no
effect on pain.
Painwasrecordedbynumericalratingscales(NRS)andby
laser-evoked potentials (LEPs) that provide evidence of pain
that is not influenced by response bias (Aslaksen et al. 2007).
Laser stimuli activate Aδ- and C-fibers which are responsible
for nociceptive processing. The typical response to a noxious
laser stimulus consists of two components, the N2 and P2.
The P2 component has been found to correlate with pain
report and is reduced during placebo analgesia (Aslaksen et
al. 2010; Colloca et al. 2008; Granovsky et al. 2008; Wager
et al. 2006; Watson et al. 2007). Placebo-induced reductions
in LEPs could mean attenuation of nociceptive input to the
brain, attentional reorientation, or reduced saliency of the
stimulus (Iannetti et al. 2008; Mouraux and Iannetti 2009;
Wager et al. 2006).
It was predicted that (1) caffeine should increase
subjective arousal. (2) Subjects should report being more
certain that they had received a painkiller after adminis-
tration of 4 mg/kg bw caffeine compared to 0 mg/kg bw
caffeine. (3) Information that a painkiller had been
administered should decrease pain and LEPs. (4) Infor-
mation that a painkiller had been administrated should
reduce pain and LEPs more when it was paired with
administration of caffeine, compared to the same infor-
mation without caffeine.
Method
Subjects
Twenty-three subjects (seven females, age range 17–25 years,
mean age 21 years, mean weight 74.5±15.9 kg (SD))
participated in the study. All subjects were recruited via
advertisements at the campus of the University of Tromsø,
Norway. Three subjects were excluded because they did not
experience the stimulus as painful. Hence, twenty subjects
wereincludedinthe finalanalysis.Allsubjectsgaveinformed
consent and fulfilled the inclusion criteria of no history of
serious injuries, no use of medication with the exception of
contraceptive pills, normal blood pressure, non-smokers,
non-pregnant and between menstrual phases. Only
regular coffee drinkers were included (mean coffee
consumption per day 1.71±SD 1.22). Participants were
told to abstain from nicotine and caffeine for 5 h prior to
testing. They were paid 600 NOK for participating in the
experiment (about 105 $). The experimental protocol was
in agreement with the Declaration of Helsinki and was
approved by the Regional Committee for Medical
Research Ethics North Norway (project no. 30/2008).
Drug and double-blind procedure
The study was designed by the first author who never had any
contact with the subjects. Two experimenters (onefemale) ran
the study. The experimenters knew the purpose of the study
and that caffeine could be administered. To double-blind the
study, the experimenters were informed that some of the
subjects would receive a painkiller instead of caffeine. In fact,
allsubjectsreceivedcaffeine.Thedrinkwasmixedbythefirst
author in a separate room out of view of the experimenter.
Subjects were weighed and the experimenter reported the
weight to the first author via telephone. Caffeine powder
(Coffeinum 0.15 mm; Apotekproduksjon AS, Oslo, Norway)
was administered in 1.5 dl grapefruit juice in a 4-mg/kg body
weight dose. The appropriate amount of caffeine powder was
weighed on a medical scale (Mettler P162, Mettler Toledo,
Columbus, USA) and mixed with 1.5 dl grapefruit juice with
pulp. Grapefruit juice with pulp was used because the bitter
taste effectively masks the taste of caffeine and the pulp
reduces the risk of detecting the added caffeine powder. In
order to further avoid the risk of subjects detecting white
caffeine powder in the juice the powder was crushed
thoroughly, and stirred with a small amount of juice before
addingthe restofthe juice.Finally,the first authordidavisual
inspection of the drink to check whether the powder had been
dissolved properly. To secure the double-blind procedure, the
first author placed the drink in a refrigerator in the lab while
the experimenter was performing the pretest in the shielded
chamber. Hence, there was never any visual contact between
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Laser stimulation and calibration
An Nd:YAP laser (Stimul 1340, El.En. Group, Firenze,
Italy) was used for laser-induced heat pain. The laser had a
wavelength of 1,340 nm and selectively activated Aδ- and
C-fibers. Spot diameter was set to 6 mm and duration to
4 ms. An upper limit of 4.5 J was set in order to avoid
damage to the skin. Subjects and experimenters wore
protective goggles. Laser stimulation was controlled by
TTL-pulses defined in E-prime software (Psychology
Software Tools, Inc., Pittsburgh, USA) run on a Dell
computer. The intensity of the pain stimulus was calibrated
for each subject in order to make sure subjects experienced
similar amount of pain. Subjects were seated in a comfortable
chair and instructed in how to report pain. Laser stimuli were
presented to the medial volar forearm, and the laser head was
moved randomly between each stimulus. Stimuli were
presented in an ascending series starting at 0.5 J, with an
increase rate of 0.25 J, until the subject reported 4 (pain
threshold) or higher on the NRS. The next series was
descending from 1 J above threshold, with a decrease rate of
0.25 J, until the subject reported 4 or lower on the NRS. Two
ascending and two descending series were performed. Pain
threshold was determined as the average stimulus intensity
where the subject reported the lowest level of pain. The
stimulus intensity to be applied in the test phase in the four
experimental conditions was 1.5 times pain threshold, or
maximum of 4.5 J.
Procedure
The experiment was performed in a laboratory at the
Department of Psychology between 9 a.m. and 6 p.m. The
lab contained a chamber (2.8×2.8 m) shielded for electro-
magnetic disturbance and sound in which the pain tests and
EEG recordings were done. Apparatus for control of painful
stimulation and for recording of EEG were placed outside the
chamber.
On the day of testing, subjects met between 9 a.m. and
4:30 p.m. Testing lasted about 90 min. On the first day, the
experimenter ascertained that the subjects met the inclusion
criteria and had read and signed the informed consent. A
cover story was presented in the informed consent form:
Subjects were informed that they participated in an
experiment that investigated the effect of expectations and
learning on the effectiveness of an over-the-counter
painkiller. The subjects were told that it was tested to what
degree the effectiveness of an over the counter painkiller
varies according to ones response expectancies. They were
further informed that this required measurement of their
response to a painful stimulus before and after receiving a
painkiller in addition to measurement of their expectations.
Finally, in order to explain why 4 days of testing were
needed, the participants were told that two tests with and
two tests without administration of a painkiller were
necessary in order to get reliable data. These four test days
were the four conditions of the balanced placebo design: a
control condition (no drug/got no drug information), a
placebo condition (no drug/got drug information), a
caffeine condition (drug/got no drug information) and an
active placebo condition (drug/got drug information). All
subjects participated in all four conditions. The order of
presentation of the conditions was different for all subjects.
After informing subjects about the purpose of the study, the
participants were weighed and the experimenter reported
the weight to the first author via telephone. Immediately
thereafter, the intensity of the laser stimulus was calibrated
for each subject according to the procedure described
above. After calibration, the electrode cap for recording of
electroencephalography was placed on the subjects. Sub-
jects were then led into the shielded chamber, placed in a
comfortable chair and told that the test phase would start.
The test phase in each experimental condition consisted of
a pretest,a pause anda posttest.Thepretest lastedabout5min
and started with measurement of stress and arousal followed
by 20 laser stimuli delivered on the T1 dermatome of the non-
dominant medial volar forearm. Immediately thereafter 1.5 dl
of chilled grapefruit juice with 0 or 4 mg/kg caffeine was
served with information that it contained an over-the-counter
painkiller that would reduce the pain (“got drug” information)
or that it contained no drug (“got no drug” information).
Subjects were toldto waitfor 30 min sothatthe drug could be
absorbed or to wait a similar amount of time when “got no
drug” information was provided. The posttest was identical to
the pretest.Immediately after the posttest, subjectswereasked
to remember and report accurately what their expectations
were at the time the posttest started.
In the pre- and posttest, each laser stimulus was signalled
by a 1 kHz tone with 1,000 ms duration that had onset 3 s
before the laser stimulus. The purpose of the auditory cue
was to produce an interval in which stimulus preceding
negativity (SPN) could be measured, which previously has
been observed in the anticipation of a painful stimulus
(Brown et al. 2008; Böcker et al. 2001). The SPN data are
not reported here. The inter-trial interval was varied
between 5 and 14.5 s in randomised order. Subjects
reported pain intensity 2–3 s after each stimulus. The laser
head was held by the experimenter who sat beside the
participant in the shielded chamber and moved it between
each stimulus in order to avoid sensitization, habituation or
skin damage.
The participants met four times in the laboratory with a
minimum of 24 h between each test. With the exception of
Psychopharmacology (2011) 215:537–548 539screening, weighing and the calibration procedure, all test
days were similar.
Pain
After each laser stimulus, subjects reported pain intensity on a
NRS where 0 represented “no sensation”, 4 represented
“barely painful” (i.e. pain threshold) and 10 “unbearable
pain”(Brownetal.2008; GarciaLarrea et al. 1997; Leandri et
al. 2006; Watson et al. 2007).
Arousal and stress
Subjective stress and arousal were reported 30 s before the
pre- and posttest by four adjective pairs from the Short
Adjective Check List (SACL; O'Neill and Parrott 1992)i n
Norwegian translation. Subjective stress was measured by
two NRSs anchored by the two adjective pairs tense–
relaxed and nervous–calm, where a score of zero indicated
completely relaxation/calmness and a score of 10 indicated
maximum tension/nervousness. Subjective arousal was
measured by two NRSs anchored by the two adjective
pairs energetic–tired and alert–drowsy, where a score of
zero indicated completely tiredness/drowsiness and score of
10 indicated maximum alertness/energetic. Stress and
arousal were expressed as the mean of the two NRSs used
for reporting of subjective stress and arousal. The items
from the SACL were chosen for their high factor loadings
on the stress and arousal factors on the SACL, similar to
earlier research on stress and arousal (O'Neill and Parrott
1992; Parrott 1993). The SACL stress scale was converted
to NRS scales.
Expectations
Reporting of expectations before the posttest could bias
pain report during the posttest, so expectancies were
measured after the posttest. Two types of expectations were
recorded: certainty of pain relief and expected pain
reduction. On the days the subjects were told they received
the drug, certainty of pain relief was measured by asking
“Answer as exact as possible what your expectations were
just before the posttest. On a scale from 0–100 were 0
means ‘not certain at all’ and 100 means ‘completely
certain’, how certain were you that the pain relieving drug
you received today would be efficient in relieving the pain”
(Arntz and Lousberg 1990). Certainty/uncertainty about
pain intensity has been found to mediate top down
influences on pain perception (Arntz and Lousberg 1990;
Brown et al. 2008).
Expected pain reduction was measured on all days by
asking: “Did you expect the pain to decrease in the posttest
compared to the pretest? YES/NO. If you were expecting a
decrease: on a scale from 0–100 were 0 means ‘no
reduction’ and 100 means ‘total reduction’, how much
reduction in pain did you expect?”. If subjects answered
“NO” to the first question, a value of zero was entered.
Recording and analysis of laser-evoked potentials
Electroencephalographic (EEG) measurements were done
from 32 electrodes (Fp1, Fp2, F7, F3, Fz, F4, F8, FC5,
FC1, FC2, FC6, T7, C3, Cz, C4, T8, TP9, CP5, CP1, CP2,
CP6, TP10, P7, P3, Pz, P4, P8, PO9, O1, Oz, O2, PO10) in
accordance with the international 10–20 system. An
electrode cap with isolated electrodes (actiCap, Brain
Products, Germany) was used. Conductive gel (SuperVisc,
EasyCap, Herrshing, Germany) was applied to all electrode
sites by a syringe with a blunt needle. Impedance was
below 5 kΩ in all channels. Common reference was
employed. The evoked potentials were recorded on a Quick
Amp EEG system (Brain Products, Germany) and analysed
off-line with Analyzer 2.0 software (Brain Products,
Germany). Data were sampled within a 0.3- and 70-Hz
bandpass with a sampling rate of 500 Hz. Electrooculog-
raphy was measured from vertical eye electrodes to control
for artefacts related to blinks and eye movements. The raw
files were re-referenced using linked ear mastoids as the
reference. A notch filter set to 50 Hz was applied off-line.
The data were segmented into epochs of 1,250 ms
including the baseline period of 250 ms. Ocular correction
was performed by an algorithm in Vision Analyser 2.0
(Gratton et al. 1983). Baseline correction was done using
the last 250 ms prior to the laser stimulus as the baseline,
before averaging the 20 pretest and 20 posttest stimuli.
Automatic peak detection was applied using 200–280 ms as
the latency window for the N2 component and 300–380 ms
for the P2 component. Finally, the first author, without
knowing to which experimental condition the files
belonged, did a visual inspection of the peaks detected in
order to rule out any errors. Only data from the Cz (vertex)
electrode were reported.
Design and statistics
The statistical analysis was performed using repeated
measures ANOVA. The design was a two information
(got drug, got no drug) by two drug (caffeine, no caffeine)
by two gender mixed design, with the first two factors as
within-subjects factors and the last factor as a between
subjects factor. Posttest minus pretest difference scores
were computed for pain intensity, LEPs, arousal and stress
and used as outcome measures. Significant interactions
between drug and information were followed up by planned
comparisons between the control and all other conditions
and between the caffeine and active placebo conditions.
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hoc test for unplanned comparisons. In the balanced
placebo design, there are two sources of information about
the placebo response: the difference between the placebo
condition and the control condition, and the difference
between the drug administered with information and
without information (Benedetti et al. 1995; Ross et al.
1962). Both of these comparisons measure the effect of
information. Accordingly, the placebo response was com-
puted in two ways: by subtracting the difference score
(posttest–pretest) in the control condition from the differ-
ence score in the placebo condition (inert placebo
response), and by subtracting the difference score in the
caffeine condition from the difference score in the active
placebo condition (active placebo response). Correlations
between these scores and the primary outcome variables
were performed using Pearson’s r (two-tailed). The level of
significance was p<0.05.
Results
Manipulation check
As a manipulation check, all subjects were asked at the end
of each test day whether they had expected a reduction in
pain in the posttest. It was hypothesised that subjects in the
control and caffeine conditions who were told that they
received no drug would expect no reduction in pain, while
subjects in the placebo and active placebo conditions who
were told that they received a painkiller should expect a
r e d u c t i o ni np a i n .S i xo f2 0s u b j e c t si nt h ec o n t r o l
condition, 11 of 20 subjects in the placebo condition, three
of 20 in the caffeine condition, and 12 of 20 in the active
placebo condition expected a reduction in pain.
It was also predicted that expectancies of pain relief in the
active placebo condition should be larger compared to the
placebo condition. However, subjects were not significantly
more certain that the drug would relieve pain in the active
placebo condition (M=34.4%, SD=31.3) compared to the
placebo condition (M=22.5%, SD=18.0, t(19)=−1.65,
p=.11).
Subjective arousal
Table 1 present the pre- and posttest ratings on subjective
arousal. There was a significant main effect of drug,
F(1, 18)=9.77, p=.006, with a decrease in arousal after
0 mg/kg caffeine and no change after 4 mg/kg caffeine
(Fig. 1). The effect of information was not significant,
F(1, 18)=0.04, p=.86, nor was the interaction between
drug and information F(1, 18)=2.78, p=.11. There was no
main effect or interactions including gender.
Subjective stress
The pre- and posttest ratings are presented in Table 2. There
were no significant main effects or interaction in the
ANOVA.
Pain intensity
The pain intensity data are displayed in Fig. 2a and Table 3.
The ANOVA showed a main effect of drug, F(1, 18)=7.54,
p=.01, with a reduction in pain after 4 mg/kg caffeine
compared to 0 mg/kg. There was no main effect of
information (F(1, 18)=0.96, p=.34) nor any interaction
between drug and information (F(1, 18)=0.31, p=.58).
There was no main effect or interactions including gender.
In order to assess whether there were any changes over
time in placebo responding, the 20 pre- and posttest stimuli
were collapsed into four blocks of five stimuli in each test.
The four blocks in the pretest was subtracted from the four
blocks in the posttest, yielding four difference scores for all
conditions. A two drug × two information × four block-
Table 1 Pre-, post- and difference scores on arousal in all conditions
(n=20, mean±SEM)
Control Placebo Caffeine Active placebo
Pre 5.1±0.4 4.8±0.4 4.6±0.4 4.5±0.4
Post 4.1±0.5 4.1±0.4 4.8±0.4 4.5±0.4
Difference −1.0±0.3 −0.7±0.2 0.2±0.2 0.0±0.2
Fig 1 Arousal. Mean subjective arousal (± SEM) in all four
conditions before and after administration of the drink
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interaction F(3, 57)=4.79, p=.005. Trend analyses showed
that there was a significant decrease across blocks in the
active placebo condition (linear trend F(1, 19)=8.34,
p=.009), but not in the other conditions. There were no
differences in pain over time between the placebo and
control condition. Pain was lower in the fourth block in the
active placebo condition compared to the caffeine condition
(F(1, 19)=8.17, p=.01; Fig 2b).
Table 2 Pre-, post- and difference scores on stress in all conditions
(n=20, mean±SEM)
Control Placebo Caffeine Active placebo
Pre 2.2±0.2 2.2±0.3 2.0±0.3 2.0±0.3
Post 1.6±0.3 1.8±0.3 1.7±0.3 1.5±0.2
Difference −0.6±0.2 −0.4±0.2 −0.3±0.1 −0.5±0.2
Fig. 2 Pain report. a Mean pain intensity (± SEM) across conditions.
Subjects reported larger reductions in pain after 4 mg/kg caffeine
(caffeine, active placebo) compared to after 0 mg caffeine (control,
placebo). b Pain reduction displayed as the difference scores (posttest–
pretest) for all four blocks of the posttest and pretest (mean±SEM). A
significant interaction between drug, information and block was
observed towards the end. This was due to the difference between
the active placebo and caffeine conditions. A steady increase in pain
relief was observed in the active placebo condition, whereas pain
relief was disrupted in the caffeine condition. c Certainty of pain
relief correlated with pain reduction in the active placebo condition
(r=−.55, p=.012). d Active placebo responding (difference score
active placebo − difference score caffeine) (positive scores indicate
larger reduction in pain in the active placebo condition) correlated
with certainty of pain relief (r=46, p=.039)
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N2 amplitude The N2 data are presented in Table 4 and
Fig. 3. The ANOVA showed an effect of drug that
approached significance, F(1, 18)=4.38, p=.051, with a
tendency towards larger reduction in N2 amplitude after
4 mg/kg caffeine compared to 0 mg/kg. There were no
other main effects or interactions (Fig. 3a).
N2 latency There were no significant main effects or
interactions between drug and information in the N2
latency data.
P2 amplitude The P2 data are presented in Table 5 and
Fig. 4. The ANOVA showed no main effects of drug,
information or gender. Neither was there an interaction of
drug and information. There was, however, a significant
interaction between information and gender F(1, 18)=
4.66, p=.04. Larger reductions of P2 amplitude was
observed in males given drug information compared to
women given the same information (p=.049). The post
hoc test showed a significant reduction in P2 amplitude in
the placebo condition compared to the control condition
for men (F(1, 18)=11.28, p=.003), but not for women.
There was no difference between the active placebo
condition and the caffeine condition for either men or
women.
P2 latency There were no significant main effects or
interactions in the P2 latency data.
Order of conditions
Order of conditions had no main effect and did not interact
with any of the other variables.
Correlations between the outcome variables
Arousal and expectancy It was hypothesised that increased
arousal in the active placebo condition should enhance
expectancies of treatment efficacy. There was, however, no
correlation between increased arousal and certainty of pain
relief in the active placebo condition (r(18)=−.06).
Arousal and pain Pre- to posttest differences in arousal did
not correlate with pain difference scores in any of the
conditions.
Stress and expectancy In the active placebo condition,
subjects that were more certain of pain relief had larger
decreasesinstressfromthepretesttotheposttest(r(18)=−.51,
p=.02). There was no correlation between certainty of pain
relief and stress reduction in the placebo condition.
Stress and pain Stress reduction correlated with pain
reduction in the active placebo condition (r(18)=.50,
p=.03), but not in any of the other conditions.
Expectancy and pain In the active placebo condition,
subjects that were more certain of pain relief reported
larger reductions in pain (r(18)=−.56, p=.01; Fig.2c).
Certainty of pain relief also correlated with the active
placebo response variable (r(18)=.46, p=.04; Fig 2d):
Subjects that were more certain of pain relief responded
with larger pain reduction in the active placebo condition
compared to the caffeine condition. No correlation was
observed in the placebo condition between certainty of pain
relief and reduction in pain or between certainty of pain
relief and the placebo response variable.
Pain and ERPs A positive correlation was observed between
the pain intensity difference score and the N2 amplitude
difference score in the placebo condition (r(18)=.48, p=.03)
and the active placebo condition r(18)=.54, p=.01. Subjects
with larger reductions in N2 amplitude reported larger
reductions in pain (Fig. 3b and c, respectively). The same
was true for P2 amplitude and pain: Subjects with larger
reductions in P2 amplitude reported larger reductions in pain
in both the placebo condition (r(18)=.49, p=.03) and active
placebo condition (r(18)=.60, p=.006; Fig. 4b and c,
respectively). There were no correlations between pain and
ERPs in the control or caffeine conditions.
Table 3 Pre-, post- and difference scores on pain in all conditions
(n=20, mean±SEM)
Control Placebo Caffeine Active placebo
Pre 5.5±0.3 5.3±0.2 5.5±0.3 5.3±0.3
Post 5.6±0.3 5.2±0.2 5.1±0.3 4.7±0.2
Difference 0.1±0.2 −0.1±0.2 −0.4±0.1 −0.6±0.2
Control Placebo Caffeine Active placebo
Pre −9.5±1.9 −11.2±1.9 −10.9±1.9 −10.4±2.0
Post −6.8±1.9 −9..0±1.8 −7.4±1.5 −6.5±1.4
Difference −2.7±1.4 −2.2±1.0 −3.5±0.8 −3.9±1.0
Table 4 Pre-, post- and differ-
ence scores on N2 in all
conditions (n=20, mean±SEM)
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The hypothesis that side effects of caffeine can enhance
expectancies and the placebo response was tested. Four
milligrammes per kilogramme of caffeine increased arousal
compared to 0 mg/kg, but did not enhance expectancies of
drug efficacy. Information that a painkiller had been
administered did not reduce pain compared to information
that no drug had been administered. However, a placebo
response on P2 amplitude was observed in males. Four
milligrammes per kilogramme of caffeine reduced pain
compared to 0 mg/kg. The mean pain relief of caffeine
administered with information that it was a painkiller was
not significantly different from caffeine administered with
“no drug” information. However, the pain relieving effect
of caffeine was disrupted after about 4 min of the posttest in
the caffeine condition, but increased steadily over time in
the active placebo condition, showing that information
modulated the analgesic effect of caffeine. The modulation
of caffeine’s analgesic effect by information was partly due
to expectancies of pain relief, but was not related to the
arousing effects of caffeine.
Information
Information that an over-the-counter painkiller had been
administered did not reduce reported pain compared to
information that no drug had been administered. This is in
line with Colloca et al. (2008) who found that an inert
cream administered with verbal suggestions that it was
analgesic had no effect on reported pain. The results of the
current study showed that subjects given drug information
were relatively uncertain about the effectiveness of the
painkiller. Probably, subjects were not convinced by the
verbal information and consequently expectancies about
pain relief were low. However, pain reduction in the
Table 5 Pre-, post- and difference scores on P2 in all conditions
(n=20, mean±SEM)
Control Placebo Caffeine Active placebo
Pre 19.5±2.0 20.0±1.9 19.2±2.2 19.3±2.0
Post 19.5±2.3 17.1±1.7 17.2±2.0 16.7±1.8
Difference 0.0±0.6 −2.9±1.0 −2.0±1.0 −2.6±1.1
Fig. 3 N2 amplitudes. a Mean N2 amplitudes (± SEM) across
conditions. There was a tendency towards a larger reduction in N2
amplitude after 4 mg/kg caffeine compared to 0 mg. b Reduction in
N2 amplitude correlated with reduction in pain in the placebo
condition (r=.48, p=.03). c Reduction in N2 amplitude correlated
with reduction in pain in the active placebo condition (r=.54, p=.01)
b
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reduction, showing that pain report was reliable.
There was a significant interaction of gender by
information due to smaller P2 amplitudes in males in the
placebo condition compared to the control condition. The
reduction in P2 amplitude could be interpreted as a decrease
in nociceptive processing in the brain, although it did not
cause a placebo effect on pain report for men. This effect
must be interpreted with caution due to the small sample.
However, the finding is similar to the effect found in
Alsaksen et al. (2010), from the same laboratory, who also
found a placebo effect on P2 amplitude for males only.
Placebo analgesia can activate an endogenous descending
pain inhibitory pathway implicating the release of endog-
enous opioids (Eippert et al. 2009a, b). Hence, one
possibility is that this pathway was activated more
strongly in males than females. One way to trigger
endogenous analgesia is by diffuse noxious inhibitory
control (DNIC). Some studies report gender differences in
DNIC with a more effective inhibition of pain in males
(Pud et al. 2009; Staud et al. 2003), although some report
no gender differences (Lautenbacher et al. 2008). Alter-
natively, the endogenous inhibitory pathway is function-
ally equivalent in males and females, but they respond
differently to verbal information about analgesia. For
instance, information that a painkiller had been adminis-
tered might have dampened physiological stress and
arousal in males, but not females. Reductions in physio-
logical arousal can decrease laser-evoked vertex potentials
(Beydoun et al. 1993). Although the present gender
difference must be treated with caution, future studies
should address the possible gender differences in endog-
enous pain inhibition and placebo responding.
The placebo effect on P2 amplitude did not cause a
placebo effect on pain intensity for males. Aslaksen et al.
(2010) found no placebo effect on pain intensity, although a
placebo effect was observed on pain unpleasantness. In
Colloca et al. (2008), a placebo effect was observed on P2
amplitude, but not on pain intensity. One possible explana-
tion is that P2 amplitude reduction must exceed a certain
magnitude in order to produce a unit reduction in pain
report (Colloca et al. 2008). A small reduction in P2
amplitude would constitute an ambiguous signal for the
subject with a consequent uncertainty as to whether pain
was reduced in the posttest or not (Allan and Siegel 2002).
The sensory information may or may not be interpreted as a
reduction in pain depending on expectancies and suggest-
ibility (Morton et al. 2010).
Fig. 4 P2 amplitudes. a Mean P2 amplitudes (± SEM) across
conditions. b There was a correlation between reduction in P2
amplitude and reduction in pain in the placebo condition (r=.49,
p=.03). c Reduction in P2 amplitude correlated with reduction in pain
in the active placebo condition (r=.59, p<.01)
b
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A dose of 4 mg/kg caffeine decreased pain compared to 0 mg.
Keogh and Witt (2001) tested the effect of 250 mg caffeine
versus placebo on pain threshold, pain tolerance and VAS
ratings of pain intensity and unpleasantness. Blood pressure
was measured in order to determine whether it had any
mediating effect. It was found that caffeine increased blood
pressure, pain threshold and pain tolerance compared to
placebo, while there were no effects on pain intensity and
unpleasantness ratings. Pain tolerance was positively corre-
lated with systolic blood pressure, indicating a link between
caffeine-induced analgesia and blood pressure. This is in line
with studies on the relationship of hypertension to pain. Both
hypertensives, and normotensives with induced high blood
pressure, exhibit decreased pain sensitivity compared to
normotensives, or normotensives with low blood pressure,
respectively. Unfortunately, no measure of cardiovascular
activity was taken in the present study and it is not possible
to draw any conclusions regarding the mechanism of
caffeine’s analgesic effect. Measures of blood pressure and
heart rate should be considered in future studies.
Arousal decreased after 0 mg/kg caffeine, whereas arousal
after 4 mg/kg caffeine was the same as in the pretest. This is
evidence that caffeine increased subjective arousal compared
to control levels, which is consistent with previous research
(Flaten and Blumenthal 1999;M i k a l s e ne ta l .2001).
T h ee f f e c to fd r u go nN 2a m p l i t u d ea p p r o a c h e d
significance. There were also reductions in P2 amplitude
in both the caffeine and active placebo conditions, but a
main effect of drug might have been masked by the
comparable reduction in the placebo condition. These data
must be interpreted in light of the effect arousal has on
LEPs. Beydoun et al. (1993) found that laser stimuli evoked
s m a l l e rN 2( 2 4 %r e d u c t i o n )a n dP 2( 5 4 %r e d u c t i o n )
amplitudes when delivered during drowsiness compared to
wakefulness, and evoked no response during stage 2 sleep.
Consequently, differences in physiological arousal between
4 and 0 mg/kg caffeine could have masked differences in
LEPs due to nociceptive processing.
There were significant correlations between reductions
in N2 and P2 amplitude and reduction in pain in the active
placebo condition, showing that pain report was reliable
and reflected cortical processing of nociceptive input. There
were no correlations between N2 and P2 amplitude
reduction in the caffeine condition, indicating that the
neural mechanisms underlying pain perception and LEPs
are partly different.
Drug × information
Information that a painkiller had been administered
increased the duration of the analgesic effect of caffeine.
The pain relieving effect of caffeine was disrupted in the
last block of the posttest when caffeine was administered
with no drug information. On the other hand, pain relief
increased steadily in the posttest when caffeine was
administered with drug information. This resulted in a
significantly larger reduction of pain in the last block of the
active placebo condition compared to the caffeine condi-
tion. The effect of information is consistent with previous
research showing that information can modulate the effect
of drugs. For instance, Flaten et al. (1999)a d m i n i s t e r e de i t h e r
placebo or the muscle relaxant carisoprodol with relaxant,
stimulant information, or no information. Carisoprodol
administered with no information or relaxant information
decreased tension. A placebo administered with information
that it acted as a stimulant increased subjective tension.
When carisoprodol was administered with information that it
acted as a stimulant, tension increased. Moreover, tension
increased even more in the presence of carisoprodol than
when the same information was administered together with a
placebo. As serum concentrations of carisoprodol increased,
so did reported tension. Most likely, information that a
stimulant drug had been administered induced expectancies
of stimulant effects with a resultant increase in tension.
Interoceptive cues from carisoprodol then provided
subjects with information that was interpreted in the
direction suggested by the verbal information. Hence,
expectancies of stimulant effects were updated and
boosted by interoceptive cues from the drug. The results of
the present study are consistent with such a reciprocal
relationship between information and drug. Information that
a painkiller had been administered had no effect on pain
perception in the presence of 0 mg/kg caffeine. On the other
hand, information induced a weak increase in the analgesic
effect of 4 mg/kg caffeine. This suggests that, as in the study
byFlatenetal.(1999), the drug provided an interoceptive cue
that interacted with the verbal information.
It was hypothesised that increased arousal after caffeine
would provide an interoceptive cue that would enhance
expectancies of pain relief and thereby increase the placebo
analgesic response in the active placeco condition com-
pared to the placebo condition. However, arousal after
4 mg/kg caffeine did not increase compared to the pretest.
Thus, the interoceptive cue generated by caffeine was most
likely weak. Consequently, no significant enhancement of
expectancies was observed in the active placebo condition.
Neither was there any correlation between arousal and
expectancies in the active placebo condition, or between
arousal and pain generally.
Possibly, the effect of information in the active placebo
condition was related to the analgesic effect of caffeine. In a
study by Vase (2005), patients with irritable bowel
syndrome were administered an inert placebo or lidocaine
for their pain. Expected pain was measured both after 5 and
546 Psychopharmacology (2011) 215:537–54822 min. Expectancies explained more of the variance in
placebo responding 25–40 min after administration of
placebo compared to 5–20 min after. This was probably
due to an initial decrease in pain during the first 20 min that
matched and enhanced subject’s expectancies, i.e. expec-
tancies were updated and increased by personal experience
of reduced pain. In the present study, the pain relieving
effect of caffeine could have functioned as an interoceptive
cue that updated and increased subject’s expectancies of
pain relief. This could explain why subjects that were more
certain of pain relief were more likely to report larger pain
relief in the active placebo condition and more likely to
show an active placebo response. This is in accordance with
the active placebo hypothesis suggested by several authors
(Dinnerstein and Halm 1970; Flaten et al. 2004, 1999;
Thomson 1982).
Laser-evoked potentials were recorded in order to rule out
possible effects of response bias and to determine whether
reduced pain was related to inhibition of nociceptive process-
ing in the brain. There were significant correlations between
reductions in LEPs and reductions in pain in the active
placebo condition showing that reductions in pain were not
due to response bias.
Limitations and future directions
The analgesic effect of caffeine could have masked the
effect of information in the active placebo condition.
Consequently, only eight subjects showed larger reduc-
tions of pain in the active placebo condition compared to
the caffeine condition. In future studies, a drug with no
analgesic effects could be used to induce interoceptive
cues. For instance, it has been reported that a bolus
infusion of the non-selective beta adrenergic agonist
isoproterenol induced changes in interoceptive awareness
in all participants (Khalsa et al. 2009). Measures of blood
pressure and heart rate should be recorded in order to
assess correlations between subjective and physiological
effects.
Verbal information that an over the counter painkiller
was administered in a drink did not induce strong
expectancies of treatment efficacy. Probably, administration
of capsules, or injections, with stronger suggestions of pain
relief will induce stronger placebo responses. The inclusion
of an additional posttest could also be considered in order
to assess the temporal characteristics of drug by information
interactions.
Conclusions
The results of the present study indicate that the effect of a
drug can modulate expectancies of treatment effects with a
consequent change in the drug response. Hence, the
assumption of placebo-controlled clinical trials that the
only difference between the drug group and the placebo
group consist in the pharmacological actions of the drug
might under certain circumstances be mistaken. Further
research should be conducted into how information and
drugs interact.
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